These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1013 related items for PubMed ID: 19660723

  • 1. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
    Majhail NS, Challa TR, Mulrooney DA, Baker KS, Burns LJ.
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
    [Abstract] [Full Text] [Related]

  • 2. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [Abstract] [Full Text] [Related]

  • 3. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
    Ando M, Ohashi K, Akiyama H, Sakamaki H, Morito T, Tsuchiya K, Nitta K.
    Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 5. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 7. Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
    Nivison-Smith I, Simpson JM, Dodds AJ, Ma DD, Szer J, Bradstock KF.
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1323-30. PubMed ID: 19747641
    [Abstract] [Full Text] [Related]

  • 8. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.
    McAvoy S, Baker KS, Mulrooney D, Blaes A, Arora M, Burns LJ, Majhail NS.
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1231-6. PubMed ID: 20302963
    [Abstract] [Full Text] [Related]

  • 9. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.
    Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau JL, Masszi T, Zander A, Békássy A, Crawley C, Arat M, Sica S, Lutz P, Socié G, EBMT Late Effects Working Party.
    Haematologica; 2008 Aug; 93(8):1203-10. PubMed ID: 18556401
    [Abstract] [Full Text] [Related]

  • 10. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation.
    Dvorak CC, Steinbach WJ, Brown JM, Agarwal R.
    Bone Marrow Transplant; 2005 Oct; 36(7):621-9. PubMed ID: 16044133
    [Abstract] [Full Text] [Related]

  • 11. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [Abstract] [Full Text] [Related]

  • 12. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
    Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, Kaneda M, Kobayashi H, Kobayashi R, Koda K, Kurosawa M, Masauji N, Matsunaga T, Mori A, Mukai M, Nishio M, Noto S, Ota S, Sakai H, Suzuki N, Takahashi T, Tanaka J, Torimoto Y, Yoshida M, Fukuhara T.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
    [Abstract] [Full Text] [Related]

  • 13. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation.
    Kersting S, Hené RJ, Koomans HA, Verdonck LF.
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1169-75. PubMed ID: 17889353
    [Abstract] [Full Text] [Related]

  • 14. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 15. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR.
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [Abstract] [Full Text] [Related]

  • 16. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
    Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, Rocha V, Larghero J, Adès L, Ribaud P, Mary JY, Socié G.
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR.
    Pediatr Blood Cancer; 2009 Dec 15; 53(7):1289-94. PubMed ID: 19731318
    [Abstract] [Full Text] [Related]

  • 19. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
    Kataoka K, Nannya Y, Ueda K, Kumano K, Takahashi T, Kurokawa M.
    Bone Marrow Transplant; 2010 Mar 15; 45(3):513-20. PubMed ID: 19684632
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.
    Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC.
    Bone Marrow Transplant; 2010 Feb 15; 45(2):295-302. PubMed ID: 19597425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.